Gasp1:a follistatin domain containing protein
CA 2476887 A1 · Owner: Hill, Jennifer J. · Inventors: Wolfman, Neil M.; Hill, Jennifer J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of a protein GASP1, comprising at , least one follistatin domain tomodulate the level or activity of growth and differentiation factor -8 (GDF-8). More particularly the invention relates to , the use of GASP1 for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism adipose tissue, and , bone degeneration.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 21, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.